MUMBAI (Reuters) - Glenmark Pharmaceuticals Ltd said on Wednesday its experimental new molecule for the treatment of diabetes, Melogliptin, is likely to start final stage global clinical trials by end-2009. Melogliptin has completed phase IIb, or mid-stage, clinical trials and the results showed improved glycemic control in patients with type 2 diabetes mellitus, Glenmark said. The results of the 12-week study conducted on 494 patients also showed low incidence of hypoglycemia, or low blood sugar level, and a neutral effect on body weight in patients taking Melogliptin, the company said in a statement. Mumbai-based Glenmark continues to be in talks to outlicense the molecule, it added in the statement. Last February, Merck KGaA ended a deal with the Indian drug maker to globally market and develop the molecule, as part of the German drugmaker's global strategy to get out of diabetes research.
No comments:
Post a Comment